HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Proposal of RAS-diuretic vs. RAS-calcium antagonist strategies in high-risk hypertension: insight from the 24-hour ambulatory blood pressure profile and central pressure.

Abstract
I here propose an individualized renin angiotensin system (RAS) inhibitor-based combination therapy with calcium-channel blockers (CCBs) or with diuretics, based on the 24-hr ambulatory blood pressure (BP) profiles and central pressure in relation to the target organ damage in high-risk hypertensive patients. For high-risk patients with increased circulating volume, such as that caused by chronic kidney disease (CKD) or congestive heart failure (CHF), who are likely to exhibit a non-dipper/riser pattern of nocturnal BP fall, diuretics are recommended in combination with a RAS inhibitor to reduce nocturnal BP preferentially. For high-risk patients with arterial diseases such as cardiovascular disease and increased arterial stiffness, who are likely to exhibit exaggerated BP variability, such as morning BP surge and day-to-day BP variability, a CCB is recommended for use in combination with a RAS inhibitor to reduce BP variability and central BP. In particular, bedtime dosing of a RAS inhibitor targeting sleep-early morning activation of RAS may be particularly effective for cardiorenal protection.
AuthorsKazuomi Kario
JournalJournal of the American Society of Hypertension : JASH (J Am Soc Hypertens) 2010 Sep-Oct Vol. 4 Issue 5 Pg. 215-8 ISSN: 1933-1711 [Print] United States
PMID20728424 (Publication Type: Editorial)
CopyrightCopyright © 2010 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Calcium Channel Blockers
  • Diuretics
Topics
  • Blood Pressure Monitoring, Ambulatory
  • Calcium Channel Blockers (therapeutic use)
  • Diuretics (therapeutic use)
  • Drug Therapy, Combination
  • Humans
  • Hypertension (diagnosis, drug therapy, epidemiology)
  • Renin-Angiotensin System (drug effects)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: